BIG3 inhibits insulin granule biogenesis and insulin secretion

Hongyu Li1,2, Shunhui Wei2, Kenneth Cheng3,4, Natalia V Gounko1,5, Russell E Ericksen2, Aimin Xu3,4,6, Wanjin Hong1,6* & Weiping Han2,*

Abstract

While molecular regulation of insulin granule exocytosis is relatively well understood, insulin granule biogenesis and maturation and its influence on glucose homeostasis are relatively unclear. Here, we identify a novel protein highly expressed in insulin-secreting cells and name it BIG3 due to its similarity to BIG/GBF of the Arf-GTP exchange factor (GEF) family. BIG3 is predominantly localized to insulin- and clathrin-positive trans-Golgi network (TGN) compartments. BIG3-deficient insulin-secreting cells display increased insulin content and granule number and elevated insulin secretion upon stimulation. Moreover, BIG3 deficiency results in faster processing of proinsulin to insulin and chromogranin A to β-granin in β-cells. BIG3-knockout mice exhibit postprandial hyperinsulinemia, hyperglycemia, impaired glucose tolerance, and insulin resistance. Collectively, these results demonstrate that BIG3 negatively modulates insulin granule biogenesis and insulin secretion and participates in the regulation of systemic glucose homeostasis.

Keywords insulin granule biogenesis; insulin resistance; insulin secretion; metabolism; proinsulin processing

Subject Categories Membrane & Intracellular Transport; Metabolism; Physiology

DOI 10.1002/embr.201338181 | Received 1 November 2013 | Revised 14 March 2014 | Accepted 34 March 2014 | Published online 7 April 2014

EMBO Reports (2014) 15, 714–722

Introduction

Insulin is the key molecule to regulate glucose homeostasis [1], and pancreatic β-cells are the primary source of insulin production and release [2]. Besides defects in insulin secretion, increased proinsulin levels are seen in patients with abnormal fasting glucose, impaired glucose tolerance, and overt diabetes and are used as a predictive marker for disease onset [1,3,4]. Elevated proinsulin levels may be due to defects in proinsulin processing and disproportionate proinsulin release, both of which occur in immature secretory granules (ISGs), the major organelles that store and process proinsulin [5]. Although insulin secretion process is well defined [6], the mechanisms underlying insulin granule biogenesis and maturation and its influence on systemic glucose homeostasis remain unclear.

The biogenesis of post-Golgi secretory vesicles is under the tight control of Arf GTPases and coat proteins [7–10]. Precise temporal and spatial activation of Arf proteins is controlled by their corresponding Arf-GTP exchange factors (GEFs) [11–13]. Both the formation and maturation of ISGs require functional Arf and brefeldin A (BFA)-sensitive Arf-GEFs [14,15]. The GBF/BIG subfamily of proteins is the only known BFA-sensitive Arf-GEFs. Moreover, proinsulin exits the trans-Golgi network (TGN) via clathrin-coated compartments [16–18], which requires Arf1 and BFA-sensitive Arf-GEF [8,11,12,19].

The insulin secretory granule contains a wide range of proteins that coordinate and regulate its behavior [20]. Multiple proteomic studies reveal a large number of unknown or uncharacterized proteins that are associated with insulin granules [20,21]. While searching for novel regulators of membrane trafficking by database mining, we identified a large Sec7 domain-containing protein, BIG3 as a novel insulin granule-associated protein. Here, we report functional studies of BIG3 in insulin granule biogenesis, insulin secretion, and glucose homeostasis.

Results and Discussion

BIG3 is a novel insulin granule-associated protein

In a search for novel regulators of the insulin secretion pathway, we found the gene kiaa1244 with a high tissue-specific expression pattern. As the novel protein showed a significant sequence similarity to the GBF/BIG subfamily of Arf-GEF proteins, it was named BIG3. BIG3 was highly expressed in pancreatic islet, and to a lesser
Figure 1. BIG3 associates with insulin granules and negatively regulates insulin secretion.

A BIG3 protein expression profile in adult mouse tissues.
B Immunostaining of mouse pancreas section showing BIG3 presence in insulin-positive cells.
C Immunoblot of isolated mouse islet showing co-localization of BIG3 and insulin.
D Representative electron microscopy (EM) image of mouse pancreatic β-cells. 87 ± 3% of BIG3 antibody-labeled gold particles (arrow heads) localized to insulin granules. N = 20 randomly selected images of β-cells.
E Immunoblot for BIG3 and other proteins in BIG3-knockdown (BKD) and control (Ctrl) cells.
F, G Insulin secretion time course (F) and quantification (area under curve, 0–60 min; G) in BKD and control cells under basal (2.8 mM glucose) and stimulated (16.7 mM glucose) condition in the absence or presence of 50 mM KCl (indicated as K). Data are presented as mean ± s.e.m. N = 6, *P < 0.05, **P < 0.01, t-test.
H, I Representative membrane capacitance recordings (H) and calculated exocytosis events (I) from capacitance increases in BKD and control cells. Data are presented as mean ± s.e.m. N = 12–19, **P < 0.01, t-test.
J Capacitance measurements of hBIG3 overexpression in BKD and control cells. Data are presented as mean ± s.e.m. N = 10–12, **P < 0.01, t-test.

BIG3 has a negative regulatory role in insulin secretion

BIG3 was highly expressed in several insulin-secreting β-cell lines, including MIN6 (Supplementary Fig S2). To analyze the cellular functions of BIG3, we first generated stable BIG3 knockdown (BKD) and scrambled control MIN6 cells by using lentiviral infection and FACS. BIG3 protein level in BKD cells was efficiently suppressed, while the expression levels of selected constitutive or vesicle-associated proteins were unaffected (Fig 1E). We next investigated the functions of BIG3, we first generated stable BIG3-knockdown (BKD) and control MIN6 (Supplementary Fig S2). To analyze the cellular functions of BIG3, we first generated stable BIG3 knockdown (BKD) and scrambled control MIN6 cells by using lentiviral infection and FACS. BIG3 protein level in BKD cells was efficiently suppressed, while the expression levels of selected constitutive or vesicle-associated proteins were unaffected (Fig 1E). We next investigated the functions of BIG3, we first generated stable BIG3 knockdown (BKD) and scrambled control MIN6 cells by using lentiviral infection and FACS. BIG3 protein level in BKD cells was efficiently suppressed, while the expression levels of selected constitutive or vesicle-associated proteins were unaffected (Fig 1E).

Generation of BIG3-knockout mice

To study the in vivo effects of BIG3 ablation on islet function and consequent impact on systemic glucose homeostasis, we generated a BIG3-knockout mouse (BKO) by targeting the 12th exon, the largest exon encoding the majority of BIG3’s Sec7 domain (Fig 2A). BIG3 gene knockout was verified by PCR of the neo-insertion from genomic DNA (Fig 2B), and protein absence was confirmed by Western blot in brain and islet lysates (Fig 2C and D) and by immunohistochemistry in pancreas (Supplementary Fig S3). Deletion of BIG3 had no effect on the expression of other BIG proteins and insulin (Supplementary Fig S4). BKO, generated initially on a C57BL/6J-129/Sv mixed background, was backcrossed to 129/Sv mice for eight generations to generate a pure 129/Sv background. BKO mice were viable and fertile with normal body weight gain (Fig 2E).

Increased insulin secretion in BKO islets

We next examined insulin secretion from isolated intact islets of BKO and control mice. Upon stimulation with high glucose, BKO islets exhibited a marked increase in first phase and total insulin secretion (Fig 2J and K). Depolarization-evoked exocytosis from isolated BKO β-cells increased approximately twofold compared to control at both early (immediately releasable pool) and late (releasable pool) time points (Fig 2L and M). EM analysis revealed that BKO β-cells had approximately 35% increase in the number of insulin granules when compared to control cells, while the size of dense core was similar (Fig 2N–P). We also observed a 50% increase in islet insulin and proinsulin content when measured by ELISA (Fig 2Q and R). In contrast, no difference was observed in the overall islet morphology, islet area, islet number, or islet size between BKO and control mice (Fig 2S–V). Together, these results indicate that BIG3 deficiency leads to elevated insulin content, insulin granule number, and enhanced secretion upon stimulation at the cell and islet level.

Abnormal glucose homeostasis in BKO mice

We next analyzed whether the altered insulin secretion at the islet level affected proper glucose handling and systemic glucose homeostasis. When fed a normal chow diet, three-month-old BKO mice were hyperglycemic and hyperinsulinemic under postprandial conditions (both ad libitum and fasting-refeeding), but not after 2-h or overnight fasting (Fig 3A and B). Serum proinsulin levels and proinsulin-to-insulin ratio were the same (Fig 3C and D). BKO mice also displayed delayed glucose clearance during an oral glucose tolerance test (GTT) after overnight fasting (Fig 3E), even though insulin secretion was elevated (Fig 3F), suggesting reduced insulin sensitivity in BKO mice. Consistently, impaired glucose clearance was observed in BKO mice upon re-feeding after overnight fasting (Fig 3G). To further ascertain the insulin sensitivity status, we
Granule biogenesis from the TGN can be promoted by stimuli and inhibited by cargo protein depletion [25]. Therefore, we examined the redistribution of BIG3 upon treatment with high K⁺, which stimulates insulin release, and cycloheximide (CHX), which suppresses granule biogenesis, in reference to markers of various subcellular compartments (Fig 4B, C). After high K⁺ stimulation, the subpopulation of docked granules, characterized by CGA staining and distributed along the plasma membrane, were depleted. Conversely, freshly generated granules were still clustered close to the Golgi region, where BIG3 overlapped with CGA and γ-adaptin (Fig 4B and C), suggesting that BIG3 is actively recruited to granules and influences secretory granule production. Following CHX treatment, CGA was mostly redistributed to the plasma membrane and did not overlap with BIG3 (Fig 4B). In contrast, BIG3 dispersed slightly, but remained in proximity to the Golgi region marked by γ-adaptin (Fig 4C). The γ-adaptin staining pattern did not change significantly after either treatment, indicating that the Golgi structure remained largely unaffected (Fig 4C). Taken together, these findings suggest that BIG3 is dynamically and predominantly recruited to the TGN where nascent immature granules are generated and whose abundance directly correlates with granule biogenic activity.

**BIG3 negatively regulates insulin granule biogenesis**

Both *in vitro* KD and *in vivo* KO experiments consistently demonstrate that regulated secretion is elevated in the absence of BIG3, consistent with the notion that BIG3 is a negative modulator of insulin secretion in β-cells. Similar to other types of secretory granules, nascent insulin granules form from the TGN as ISGs with clathrin coats, followed by prohormone processing and removal of clathrin coats to generate a clathrin-free mature secretory granule (MSG) [16]. Therefore, there are typically two distinct populations of insulin/CGA-marked granules: ISGs that cluster toward the Golgi region and MSGs that spread along the plasma membrane. The fact that BIG3 is predominantly associated with insulin granules concentrated to the clathrin-patched TGN compartment suggests that BIG3 may be involved in insulin granule biogenesis. To explore the involvement of BIG3 in regulating nascent granule biogenesis, we assessed granule biogenic activity by measuring the prohormones and
corresponding mature hormones. BIG3 KD in MIN6 cell resulted in a marked increase in cellular insulin (Fig 5A) and moderate increase in proinsulin (Fig 5B) under basal conditions. In addition, mature b-granin markedly increased, along with a minor increase in the precursor CGA in BKD cells (Fig 5C and D). The proportional change of the two pairs of proteins indicates that BIG3 may have a general role in modulating secretory granules.

The decreased prohormone-to-mature-hormone ratio may be due to enhanced prohormone processing. Therefore, we measured proinsulin processing at multiple time points in MIN6 cell lysates...
after 1-h high K⁺ stimulation to promote and synchronize proinsulin synthesis, and another hour of CHX treatment to inhibit proinsulin synthesis and exocytosis. BKD cells had a significant decrease in proinsulin at 30 min, indicating that proinsulin was processed faster in BKD than in control cells (Fig 5E). The timing on proinsulin processing is in line with a previous study [26]. We also determined CGA processing in BKD cells by pulse-chase labeling of newly made proteins with 35S-methionine and found faster conversion of CGA to β-granin in BKD cells than in control cells (Fig 5F). Since granule production is coupled with prohormone production, these findings suggest that BIG3 is involved in a negative feedback mechanism to restrain granule biogenesis. The notion is further supported by the finding that BIG3 overexpression attenuated simulated exocytosis in MIN6 cells (Fig 1J). Collectively, these results suggest that BIG3...
negatively regulates granule biogenesis: upon its removal, granule biogenesis and hormone production and storage are elevated. Consistent with preferential release of newly synthesized insulin granules [27–29], increased granule biogenesis leads to a larger pool of fresh insulin granules and consequently enhances secretion upon stimulation.

Figure 4. BIG3 dynamically localizes to trans-Golgi network (TGN)-immature secretory granule (ISG) compartment.

A–C Confocal images of MIN6 cells showing (A) TGN-granule localization of BIG3 under normal growth conditions, (B) perinuclear relocalization of BIG3 and chromogranin A (CGA) after high K⁺ and CHX treatments, and (C) intact TGN compartments during high K⁺ and CHX treatments. Scale bars = 10 μm.
The molecular mechanism by which BIG3 modulates granule biogenesis is yet to be elucidated. It is well known that proinsulin transport requires Class I Arfs and their corresponding GEFs. GBF/BIG are the only known BFA-sensitive Arf-GEF, and multiple lines of evidence have shown that both secretory granule formation from the TGN and ISG maturation require Class I Arf activity in a BFA-sensitive manner. This suggests that a yet to be identified BFA-sensitive Arf-GEF is required. It is worth noting that the single known functional domain in BIG3 by sequence analysis, the Sec7 domain, has a non-functional catalytic motif [11]. Thus, one of our hypotheses is that BIG3 acts as a competitive non-functional Arf-GEF, thereby negatively modulating granule production. The expression levels of BIG1/2 and GBF1 were not changed in BKO or BKD cells; however, whether their bioactivity in granule formation is affected remains to be studied. An alternative explanation could involve a mechanism similar to Arf4/Arf5, which binds to soma calcium-dependent activator protein for secretion (CAPS) proteins at the TGN to promote dense core vesicle formation in a guanosine diphosphate (GDP)-dependent manner, thereby bypassing the need for a functional GEF [30]. It is not clear whether a similar mechanism applies to insulin granule formation and how BIG3 is involved. Currently, we are exploring direct evidence of BIG3 engagement in granule formation. It is worth noting that BIG3 is also expressed in the brain (Fig 1A). Whether BIG3 in the CNS contributes to the observed metabolic phenotypes remains to be determined.

In summary, our study shows that BIG3 is associated with immature insulin granules and negatively modulates insulin granule biogenesis in β-cells and, in turn, insulin output by islets. Consequently, deletion of BIG3 in mice results in increased levels of circulating insulin and disrupted glucose homeostasis, including postprandial hyperglycemia and impaired glucose tolerance. Overall, our study identifies a novel regulatory mechanism for granule biogenesis and maturation that plays a significant role in modulating systemic metabolism.

Materials and Methods

All experiments involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of A*STAR. Indirect calorimetry and other physiology tests were performed as previously described [6,31,32]. For detailed information, see Supplementary Materials and Methods.
Supplementary information for this article is available online:
http://embor.embopress.org

Acknowledgements
Research in the laboratories of Hong and Han was supported by A*STAR Biomedical Research Council. A. Xu was supported by Hong Kong Research Grant Council (HKU4/CRF/10R).

Author contributions
HL, WH, and WH designed the study; HL, SW, KC, and NG performed the experiments; HL, RE, AX, WH, and WH wrote the paper; all authors were involved in data analysis and approved the manuscript.

Conflict of interest
The authors declare that they have no conflict of interest.

References